- Home
- NPFD vs ESPR Comparison
NPFD vs ESPR Comparison
Compare NPFD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- ESPR
- Stock Information
- Founded
- NPFD 2021
- ESPR 2008
- Country
- NPFD United States
- ESPR United States
- Employees
- NPFD N/A
- ESPR N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- ESPR Health Care
- Exchange
- NPFD Nasdaq
- ESPR Nasdaq
- Market Cap
- NPFD 474.6M
- ESPR 534.3M
- IPO Year
- NPFD N/A
- ESPR 2013
- Fundamental
- Price
- NPFD $19.85
- ESPR $3.07
- Analyst Decision
- NPFD
- ESPR Buy
- Analyst Count
- NPFD 0
- ESPR 6
- Target Price
- NPFD N/A
- ESPR $6.50
- AVG Volume (30 Days)
- NPFD 64.7K
- ESPR 7.2M
- Earning Date
- NPFD 01-01-0001
- ESPR 11-06-2025
- Dividend Yield
- NPFD 6.28%
- ESPR N/A
- EPS Growth
- NPFD N/A
- ESPR N/A
- EPS
- NPFD N/A
- ESPR N/A
- Revenue
- NPFD N/A
- ESPR $268,125,000.00
- Revenue This Year
- NPFD N/A
- ESPR $13.05
- Revenue Next Year
- NPFD N/A
- ESPR N/A
- P/E Ratio
- NPFD N/A
- ESPR N/A
- Revenue Growth
- NPFD N/A
- ESPR N/A
- 52 Week Low
- NPFD $14.50
- ESPR $0.69
- 52 Week High
- NPFD $18.07
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NPFD 59.63
- ESPR 71.40
- Support Level
- NPFD $19.83
- ESPR $2.35
- Resistance Level
- NPFD $20.01
- ESPR $3.41
- Average True Range (ATR)
- NPFD 0.18
- ESPR 0.17
- MACD
- NPFD -0.01
- ESPR 0.00
- Stochastic Oscillator
- NPFD 67.31
- ESPR 67.92
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.